Harmony Biosciences commercializes therapies for rare neurological disorders, led by WAKIX (pitolisant), a first-in-class histamine H3 receptor antagonist/inverse agonist for excessive daytime sleepiness and cataplexy in narcolepsy. It holds exclusive U.S. rights to pitolisant under license from France’s Bioprojet and targets patients with limited treatment options. The company focuses on unmet needs in sleep and rare neurology rather than broad primary-care markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 184.7 | — | 45.6 | -8.8% |
| Q2 2025 | 200.5 | — | 39.8 | -33.3% |
| Q3 2025 | 239.5 | — | 50.9 | -14.5% |
| Q4 2025 | 243.8 | — | 22.5 | -63.5% |
| Q1 2026 | 215.4 | 16.6% | 32.5 | -28.7% |
| Q2 2026 | 261.3 | 30.3% | 75.4 | 89.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Supernus Pharmaceuticals, Inc. (SUPN), Aurinia Pharmaceuticals Inc. (AUPH), Stagwell Inc. (STGW), ChronoScale Holdings Corporation (CHRN), Navitas Semiconductor Corporation (NVTS), Northwest Bancshares, Inc. (NWBI)